Drug intelligence / Profile preview

Atengood 50 AM

Development stage: Unknown
Lead developer: GoodMed Healthcare
Modality: Small Molecules
Administration: Oral

Overview

Atengood 50 AM is a fixed-dose combination tablet developed by GoodMed Healthcare for the management of hypertension. It contains 50 mg of atenolol, a cardioselective beta-1 adrenergic receptor blocker, and 5 mg of amlodipine, a dihydropyridine L-type calcium channel blocker. Atenolol works by reducing heart rate and cardiac output, while amlodipine promotes vasodilation by inhibiting the influx of calcium ions into vascular smooth muscle and cardiac muscle cells. This combination provides a synergistic effect, improving blood pressure control in patients who require multiple agents to reach therapeutic targets.

Brand names: Atengood 50 AMAtengood50 AMAtengood-50 AM
Other names: Atenolol 50 mg + Amlodipine 5 mg

Targets

ADRB2 (β2)ADRB1 (β1)

Beyond the preview

Go deeper on Atengood 50 AM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Atengood 50 AM.

Explore the full profile